Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets. Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations.
The company has established itself as a comprehensive pharmaceutical manufacturer with a strong focus on oncology therapeutics. Shilpa Medicare is a fully integrated pharmaceutical company, present across the entire value chain from Research and Development, Active Pharmaceutical Ingredients, Finished Formulations, Biologicals, ODF, Derma, Peptides & Polymers etc. Currently we are one of the leaders in the Oncology market and offer a complete range of products in this segment spanning across APIs, formulations both in terms of R&D and manufacturing capabilities.
The Co. is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.
The company's formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML's wholly owned subsidiary Shilpa Therapeutics. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches.
Shilpa Medicare is also advancing its biologicals and biosimilars portfolio, including monoclonal antibodies, microbial biosimilars, vaccines, and recombinant human albumin. The unit has currently several biosimilars (Monoclonal antibodies (MAbs), fusion proteins and glycoproteins) and one novel biologic in its pipeline.
Shilpa Medicare has three manufacturing facilities, out of which two are located in India. Our manufacturing units comply with all regulatory requirements having received approvals from various prominent international regulatory bodies, including the USFDA It operates production facilities across India specializing in complex APIs, formulations, biologicals, and novel drug-delivery systems.
The company's manufacturing capabilities are designed with flexibility in mind. Each of our manufacturing facilities is designed, equipped and operated to deliver high quality products within defined cost and delivery schedules. Our manufacturing facilities have flexibility to operate for wide range of batch of sizes and in various dosage forms.
The API facilities are approved by several national and international regulatory bodies like USFDA, EU, Cofepris- Mexico, PMDA-Japan, Korean FDA, TPD Canada & TGA-Australia. The company has demonstrated strong regulatory compliance with recent achievements including the USFDA has classified the inspection outcome as voluntary action indicated (VAI). The inspection was conducted at the Unit-1 facility from 3 March to 7 March 2025.
Recent regulatory milestones include Shilpa Medicare's Unit VI in Bengaluru has received Good Manufacturing Practice (GMP) approval from the European Medicines Agency, enhancing its ability to market innovative drug delivery systems in the EU and Shilpa Medicare's subsidiary, Shilpa Biologics, has obtained European GMP certification for its Dharwad plant, allowing the production of test batches following a successful inspection by Austrian authorities.
Net profit of Shilpa Medicare declined 40.78% to Rs 14.51 crore in the quarter ended March 2025 as against Rs 24.50 crore during the previous quarter ended March 2024. Sales rose 13.41% to Rs 330.80 crore in the quarter ended March 2025 as against Rs 291.69 crore during the previous quarter ended March 2024.
For the full year,net profit rose 145.65% to Rs 78.29 crore in the year ended March 2025 as against Rs 31.87 crore during the previous year ended March 2024. Sales rose 11.71% to Rs 1286.41 crore in the year ended March 2025 as against Rs 1151.60 crore during the previous year ended March 2024.
- Market Cap: ₹9618.22 Cr as of 17th June 2025
- P/E Ratio: 122.84
- P/B Ratio: 5.34
- 52-week High: ₹1000
- 52-week Low: ₹519.50
- Dividend: Rs 1 per equity share for FY 2024-2025
Shilpa Medicare's subsidiary, Shilpa Biocare, has entered a strategic partnership with Orion Corporation to distribute Recombinant Human Albumin in Europe, enhancing market access and safety. This partnership demonstrates the company's commitment to expanding its biologics footprint in regulated markets.
The current Research & Development infrastructure include Clone and bioassay development platforms, high throughput multi parallel fermentation units, conventional and continuous chromatography units, high end/high throughput analytical platform, and formulation development engine. The technologies developed at this unit have been recognised by the Department of Biotechnology, Govt. of India as amongst the most innovative in the country.
The company also provides contract research and manufacturing services (CDMO) for global clients. Shilpa Medicare provide a comprehensive service portfolio to assist researchers in applications requiring Contract Development and Manufacturing Activities.
Promoter holding in Shilpa Medicare Ltd has gone down to 44.23 per cent as of Mar 2025 from 44.39 per cent as of Jun 2024. The company maintains a balanced shareholding structure with strong institutional participation.
